{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T17:01:19Z","timestamp":1788627679766,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Insights Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Primary central nervous system post-transplantation lymphoproliferative disorder (PCNS-PTLD) is a rare but serious complication of hematopoietic stem cell transplantation (HSCT) in patients with severe \u03b2-thalassemia. This study aimed to assess the clinical presentation, pathological characteristics, neuroimaging findings, and treatment strategies in patients with \u03b2-thalassemia who developed PCNS-PTLD and to compare a case series from our transplant center to reported cases from literature.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively reviewed our hospital database and identified four cases of pathologically confirmed PCNS-PTLD without a history of systemic PTLD in patients with severe \u03b2-thalassemia after HSCT. We also performed a relevant literature review on PCNS-PTLD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median time from transplantation to diagnosis of PCNS-PTLD was 5.5 months. Intracerebral lesions were usually multiple involving both supratentorial and infratentorial regions with homogeneous or rim enhancement. All patients had pathologically confirmed PCNS-PTLD with three patients having diffuse large B-cell lymphoma and the fourth patient having plasmacytic hyperplasia. There was low response to treatment with a median survival of 83 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PCNS-PTLD should be considered in the differential diagnosis of patients with \u03b2-thalassemia who had an intracranial lesion on neuroimaging after HSCT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Critical relevance statement<\/jats:title>\n                <jats:p>This case series with a comprehensive review of neuroimaging and clinical characteristics of children with primary central nervous system post-transplantation lymphoproliferative disorder should advance our understanding and improve management of this rare yet severe complication following transplant for \u03b2-thalassemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key points<\/jats:title>\n                <jats:p>\u2022 We assessed clinical presentation, treatment strategies, and neuroimaging characteristics of PCNS-PTLD in patients with \u03b2-thalassemia after transplantation.<\/jats:p>\n                <jats:p>\u2022 Patients with \u03b2-thalassemia may have post-transplantation lymphoproliferative disorder presenting as brain lesions on neuroimaging.<\/jats:p>\n                <jats:p>\u2022 Neuroimaging findings of the brain lesions are helpful for prompt diagnosis and proper management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13244-024-01605-y","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T05:02:26Z","timestamp":1707886946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroimaging features of primary central nervous system post-transplantation lymphoproliferative disorder following hematopoietic stem cell transplant in patients with \u03b2-thalassemia: a case series and review of literature"],"prefix":"10.1186","volume":"15","author":[{"given":"Xueqing","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean W.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1563-9101","authenticated-orcid":false,"given":"Muliang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bihong T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","volume":"391","author":"AT Taher","year":"2018","unstructured":"Taher AT, Weatherall DJ, Cappellini MD (2018) Thalassaemia. Lancet 391:155\u2013167. https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6","journal-title":"Lancet"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMra2021838","volume":"384","author":"AT Taher","year":"2021","unstructured":"Taher AT, Musallam KM, Cappellini MD (2021) \u03b2-Thalassemias. Longo DL, ed. N Engl J Med 384:727\u2013743. https:\/\/doi.org\/10.1056\/NEJMra2021838","journal-title":"N Engl J Med"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3324\/haematol.2016.144428","volume":"101","author":"J Styczynski","year":"2016","unstructured":"Styczynski J, Van Der Velden W, Fox CP et al (2016) Management of Epstein-Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 101:803\u2013811. https:\/\/doi.org\/10.3324\/haematol.2016.144428","journal-title":"Haematologica"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/pbc.23134","volume":"58","author":"DK Bonney","year":"2012","unstructured":"Bonney DK, Htwe EE, Turner A et al (2012) Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant: intrathecal rituximab in CNS PTLD. Pediatr Blood Cancer 58:459\u2013461. https:\/\/doi.org\/10.1002\/pbc.23134","journal-title":"Pediatr Blood Cancer"},{"key":"1605_CR5","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1080\/10428194.2018.1474462","volume":"60","author":"S Romero","year":"2019","unstructured":"Romero S, Montoro J, Guinot M et al (2019) Post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation. Leuk Lymphoma 60:142\u2013150. https:\/\/doi.org\/10.1080\/10428194.2018.1474462","journal-title":"Leuk Lymphoma"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5114\/ceji.2015.50845","volume":"1","author":"M Wr\u00f3blewska","year":"2015","unstructured":"Wr\u00f3blewska M, Gil LA, Komarnicki MA (2015) Invasive pulmonary successful treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disease with central nervous system involvement following allogeneic haematopoietic stem cell transplantation \u2013a case study. Cent Eur J Immunol 1:122\u2013125. https:\/\/doi.org\/10.5114\/ceji.2015.50845","journal-title":"Cent Eur J Immunol"},{"key":"1605_CR7","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1309\/N82CTQ1J0XEVEFQB","volume":"121","author":"AA Castellano-Sanchez","year":"2004","unstructured":"Castellano-Sanchez AA, Li S, Qian J, Lagoo A, Weir E, Brat DJ (2004) Primary central nervous system posttransplant lymphoproliferative disorders. Am J Clin Pathol 121:246\u2013253. https:\/\/doi.org\/10.1309\/N82CTQ1J0XEVEFQB","journal-title":"Am J Clin Pathol"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lrr.2019.04.003","volume":"11","author":"H Sakamoto","year":"2019","unstructured":"Sakamoto H, Itonaga H, Taguchi J et al (2019) Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: the Nagasaki Transplant Group experience. Leuk Res Rep 11:27\u201330. https:\/\/doi.org\/10.1016\/j.lrr.2019.04.003","journal-title":"Leuk Res Rep"},{"key":"1605_CR9","first-page":"36","volume":"57","author":"T Ishikawa","year":"2016","unstructured":"Ishikawa T, Shimizu H, Takei T et al (2016) Monomorphic post-transplant T-lymphoproliferative disorder after autologous stem cell transplantation for multiple myeloma. Jpn J Clin Hematol 57:36\u201340","journal-title":"Jpn J Clin Hematol"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/j.1399-3062.2009.00409.x","volume":"11","author":"Y Aisa","year":"2009","unstructured":"Aisa Y, Mori T, Nakazato T et al (2009) Primary central nervous system post-transplant lymphoproliferative disorder presenting as cerebral hemorrhage after unrelated bone marrow transplantation. Transpl Infect Dis 11:438\u2013441. https:\/\/doi.org\/10.1111\/j.1399-3062.2009.00409.x","journal-title":"Transpl Infect Dis"},{"key":"1605_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1227\/NEU.0b013e31828cf619","volume":"72","author":"W Lake","year":"2013","unstructured":"Lake W, Chang JE, Kennedy T, Morgan A, Salamat S, Ba\u015fkaya MK (2013) A case series of primary central nervous system posttransplantation lymphoproliferative disorder: imaging and clinical characteristics. Neurosurgery 72:960\u2013970. https:\/\/doi.org\/10.1227\/NEU.0b013e31828cf619","journal-title":"Neurosurgery"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1007\/s00277-021-04548-2","volume":"100","author":"H Zimmermann","year":"2021","unstructured":"Zimmermann H, Nitsche M, Pott C et al (2021) Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Ann Hematol 100:2043\u20132050. https:\/\/doi.org\/10.1007\/s00277-021-04548-2","journal-title":"Ann Hematol"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1754-9485.2012.02366.x","volume":"56","author":"T Sutherland","year":"2012","unstructured":"Sutherland T, Yap K, Liew E, Tartaglia C, Pang M, Trost N (2012) Primary central nervous system lymphoma in immunocompetent patients: a retrospective review of MRI features: MRI of PCNSL. J Med Imaging Radiat Oncol 56:295\u2013301. https:\/\/doi.org\/10.1111\/j.1754-9485.2012.02366.x","journal-title":"J Med Imaging Radiat Oncol"},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00277-021-04433-y","volume":"100","author":"F Pegoraro","year":"2021","unstructured":"Pegoraro F, Favre C (2021) Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. Ann Hematol 100:865\u2013878. https:\/\/doi.org\/10.1007\/s00277-021-04433-y","journal-title":"Ann Hematol"},{"key":"1605_CR15","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1182\/blood-2008-09-178046","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren O, Gilbert ES, Rizzo JD et al (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113:4992\u20135001. https:\/\/doi.org\/10.1182\/blood-2008-09-178046","journal-title":"Blood"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3324\/haematol.2013.087338","volume":"99","author":"M Uhlin","year":"2014","unstructured":"Uhlin M, Wikell H, Sundin M et al (2014) Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99:346\u2013352. https:\/\/doi.org\/10.3324\/haematol.2013.087338","journal-title":"Haematologica"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.bbmt.2015.07.035","volume":"21","author":"LP Xu","year":"2015","unstructured":"Xu LP, Zhang CL, Mo XD et al (2015) Epstein-Barr virus\u2013related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 21:2185\u20132191. https:\/\/doi.org\/10.1016\/j.bbmt.2015.07.035","journal-title":"Biol Blood Marrow Transplant"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"e9055","DOI":"10.1097\/MD.0000000000009055","volume":"96","author":"X Zhang","year":"2017","unstructured":"Zhang X, Hao W, Xu T, Liu S, Jiang H (2017) Diagnosis and treatment of neoplastic post-transplant lymphoproliferative disorder following hematopoietic stem cell transplant in \u03b2-thalassemia: a pediatric case report. Medicine (Baltimore) 96:e9055. https:\/\/doi.org\/10.1097\/MD.0000000000009055","journal-title":"Medicine (Baltimore)"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1038\/sj.leu.2404818","volume":"21","author":"G Reddiconto","year":"2007","unstructured":"Reddiconto G, Chiusolo P, Fiorini A et al (2007) Assessment of cellular origin and EBV status in a PTLD after double cord blood transplantation. Leukemia 21:2552\u20132554. https:\/\/doi.org\/10.1038\/sj.leu.2404818","journal-title":"Leukemia"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.bbmt.2010.02.014","volume":"16","author":"KK Ballen","year":"2010","unstructured":"Ballen KK, Cutler C, Yeap BY et al (2010) Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant 16:1025\u20131031. https:\/\/doi.org\/10.1016\/j.bbmt.2010.02.014","journal-title":"Biol Blood Marrow Transplant"},{"key":"1605_CR21","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1182\/blood-2004-09-3740","volume":"105","author":"DC Macallan","year":"2005","unstructured":"Macallan DC, Wallace DL, Zhang Y et al (2005) B-cell kinetics in humans: rapid turnover of peripheral blood memory cells. Blood 105:3633\u20133640. https:\/\/doi.org\/10.1182\/blood-2004-09-3740","journal-title":"Blood"},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1399-3062.2011.00621.x","volume":"13","author":"NA Kittan","year":"2011","unstructured":"Kittan NA, Beier F, Kurz K et al (2011) Isolated cerebral manifestation of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case of clinical and diagnostic challenges: PTLD vs. encephalitis after alloHSCT. Transpl Infect Dis 13:524\u2013530. https:\/\/doi.org\/10.1111\/j.1399-3062.2011.00621.x","journal-title":"Transpl Infect Dis"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1016\/j.transproceed.2020.08.002","volume":"52","author":"A Mayumi","year":"2020","unstructured":"Mayumi A, Yamashita T, Matsuda I et al (2020) Toxoplasmic encephalitis followed by primary EBV-associated post-transplant lymphoproliferative disorder of the central nervous system in a patient undergoing allogeneic hematopoietic stem cell transplant: a case report. Transplant Proc 52:2858\u20132860. https:\/\/doi.org\/10.1016\/j.transproceed.2020.08.002","journal-title":"Transplant Proc"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12185-011-0951-3","volume":"94","author":"H Shimizu","year":"2011","unstructured":"Shimizu H, Saitoh T, Koya H et al (2011) Discrepancy in EBV-DNA load between peripheral blood and cerebrospinal fluid in a patient with isolated CNS post-transplant lymphoproliferative disorder. Int J Hematol 94:495\u2013498. https:\/\/doi.org\/10.1007\/s12185-011-0951-3","journal-title":"Int J Hematol"},{"key":"1605_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11060-011-0739-6","volume":"107","author":"F Lieberman","year":"2012","unstructured":"Lieberman F, Yazbeck V, Raptis A, Felgar R, Boyiadzis M (2012) Primary central nervous system post-transplant lymphoproliferative disorders following allogeneic hematopoietic stem cell transplantation. J Neurooncol 107:225\u2013232. https:\/\/doi.org\/10.1007\/s11060-011-0739-6","journal-title":"J Neurooncol"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"534","DOI":"10.4103\/0973-1482.119373","volume":"9","author":"TC Tang","year":"2013","unstructured":"Tang TC, Chuang WY, Chang H (2013) Isolated cerebral post-transplant lymphoproliferative disorder in a lymphoma recipient. J Can Res Ther 9:534. https:\/\/doi.org\/10.4103\/0973-1482.119373","journal-title":"J Can Res Ther"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"e13302","DOI":"10.1111\/petr.13302","volume":"22","author":"C Kassa","year":"2018","unstructured":"Kassa C, Rem\u00e9nyi P, Sink\u00f3 J, K\u00e1llay K, Kert\u00e9sz G, Kriv\u00e1n G (2018) Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder. Pediatr Transplant 22:e13302. https:\/\/doi.org\/10.1111\/petr.13302","journal-title":"Pediatr Transplant"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/sj.bmt.1705575","volume":"39","author":"M Hamadani","year":"2007","unstructured":"Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC (2007) Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein\u2013Barr virus DNA PCR. Bone Marrow Transplant 39:249\u2013251. https:\/\/doi.org\/10.1038\/sj.bmt.1705575","journal-title":"Bone Marrow Transplant"},{"key":"1605_CR29","first-page":"1005","volume":"42","author":"Y Azuma","year":"2015","unstructured":"Azuma Y, Nakaya A, Fujita S et al (2015) Primary central nervous system post-transplant lymphoproliferative disorder in a patient with acute lymphocytic leukemia. Gan To Kagaku Ryoho 42:1005\u20131007","journal-title":"Gan To Kagaku Ryoho"},{"key":"1605_CR30","doi-asserted-by":"publisher","first-page":"261.e1","DOI":"10.1016\/j.jtct.2020.12.019","volume":"27","author":"A Balaguer-Rosello","year":"2021","unstructured":"Balaguer-Rosello A, Pi\u00f1ana JL, Bataller L et al (2021) Central nervous system involvement in Epstein\u2013Barr virus-related post-transplant lymphoproliferative disorders after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther 27:261.e1\u2013261.e7. https:\/\/doi.org\/10.1016\/j.jtct.2020.12.019","journal-title":"Transplant Cell Ther"},{"key":"1605_CR31","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3390\/v12040416","volume":"12","author":"H Inoue","year":"2020","unstructured":"Inoue H, Rai S, Tanaka H et al (2020) Epstein\u2013Barr virus-induced post-transplant lymphoproliferative disorder of the central nervous system successfully treated with chemo-immunotherapy. Viruses 12:416. https:\/\/doi.org\/10.3390\/v12040416","journal-title":"Viruses"},{"key":"1605_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1186\/2193-1801-3-582","volume":"3","author":"H Sano","year":"2014","unstructured":"Sano H, Fujimoto M, Okuno K et al (2014) Epstein\u2013Barr virus-associated posttransplant lymphoproliferative disorder involving the central nervous system following autologous hematopoietic stem cell transplantation for neuroblastoma. SpringerPlus 3:582. https:\/\/doi.org\/10.1186\/2193-1801-3-582","journal-title":"SpringerPlus"},{"key":"1605_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.12659\/AOT.890372","volume":"19","author":"D Januszkiewicz-Lewandowska","year":"2014","unstructured":"Januszkiewicz-Lewandowska D (2014) Utility of quantitative EBV DNA measurements in cerebrospinal fluid for diagnosis and monitoring of treatment of central nervous system EBV-associated post-transplant lymphoproliferative disorder after allogenic hematopoietic stem cell transplantation. Ann Transplant 19:253\u2013256. https:\/\/doi.org\/10.12659\/AOT.890372","journal-title":"Ann Transplant"},{"key":"1605_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/sj.bmt.1701205","volume":"21","author":"K Nagafuji","year":"1998","unstructured":"Nagafuji K, Eto T, Hayashi S et al (1998) Donor lymphocyte transfusion for the treatment of Epstein\u2013Barr virus-associated lymphoproliferative disorder of the brain. Bone Marrow Transplant 21:1155\u20131158. https:\/\/doi.org\/10.1038\/sj.bmt.1701205","journal-title":"Bone Marrow Transplant"},{"key":"1605_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/BF02982135","volume":"75","author":"T Terasawa","year":"2002","unstructured":"Terasawa T, Ohashi H, Tsushita K et al (2002) Failure to detect Epstein-Barr virus (EBV) DNA in plasma by real-time PCR in a case of EBV-associated posttransplantation lymphoproliferative disorder confined to the central nervous system. Int J Hematol 75:416\u2013420. https:\/\/doi.org\/10.1007\/BF02982135","journal-title":"Int J Hematol"},{"key":"1605_CR36","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1159\/000165057","volume":"31","author":"L Kordelas","year":"2008","unstructured":"Kordelas L, Trenschel R, Koldehoff M, Elmaagacli A, Beelen DW (2008) Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab. Oncol Res Treat 31:691\u2013693. https:\/\/doi.org\/10.1159\/000165057","journal-title":"Oncol Res Treat"},{"key":"1605_CR37","doi-asserted-by":"publisher","first-page":"672052","DOI":"10.3389\/fonc.2021.672052","volume":"11","author":"TT Yang","year":"2021","unstructured":"Yang TT, Chen WH, Zhao YM, Fu HR, Huang H, Shi JM (2021) Zanubrutinib treatment of central nervous system posttransplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: a case report. Front Oncol 11:672052. https:\/\/doi.org\/10.3389\/fonc.2021.672052","journal-title":"Front Oncol"},{"key":"1605_CR38","doi-asserted-by":"publisher","first-page":"204062072091096","DOI":"10.1177\/2040620720910964","volume":"11","author":"L Liu","year":"2020","unstructured":"Liu L, Liu Q, Feng S (2020) Management of Epstein\u2013Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Ther Adv Hematol 11:204062072091096. https:\/\/doi.org\/10.1177\/2040620720910964","journal-title":"Ther Adv Hematol"},{"key":"1605_CR39","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13244-019-0726-6","volume":"10","author":"ML White","year":"2019","unstructured":"White ML, Moore DW, Zhang Y, Mark KD, Greiner TC, Bierman PJ (2019) Primary central nervous system post-transplant lymphoproliferative disorders: the spectrum of imaging appearances and differential. Insights Imaging 10:46. https:\/\/doi.org\/10.1186\/s13244-019-0726-6","journal-title":"Insights Imaging"},{"key":"1605_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00234-017-1804-4","volume":"59","author":"A Server","year":"2017","unstructured":"Server A, Bargall\u00f3 N, Fl\u00f8isand Y, Sponheim J, Graus F, Hald JK (2017) Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation. Neuroradiology 59:105\u2013126. https:\/\/doi.org\/10.1007\/s00234-017-1804-4","journal-title":"Neuroradiology"},{"key":"1605_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1215\/15228517-2-4-229","volume":"2","author":"TG Phan","year":"2000","unstructured":"Phan TG (2000) Posttransplant primary CNS lymphoma. Neuro Oncol 2:229\u2013238. https:\/\/doi.org\/10.1215\/15228517-2-4-229","journal-title":"Neuro Oncol"},{"key":"1605_CR42","first-page":"563","volume":"18","author":"BA Johnson","year":"1997","unstructured":"Johnson BA, Fram EK, Johnson PC, Jacobowitz R (1997) The variable MR appearance of primary lymphoma of the central nervous system: comparison with histopathologic features. AJNR Am J Neuroradiol 18:563","journal-title":"AJNR Am J Neuroradiol"},{"key":"1605_CR43","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuonc\/noab020","volume":"23","author":"RF Barajas","year":"2021","unstructured":"Barajas RF, Politi LS, Anzalone N et al (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol 23:1056\u20131071. https:\/\/doi.org\/10.1093\/neuonc\/noab020","journal-title":"Neuro Oncol"},{"key":"1605_CR44","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2463\/mrms.mp.2017-0135","volume":"18","author":"S Bao","year":"2019","unstructured":"Bao S, Watanabe Y, Takahashi H et al (2019) Differentiating between glioblastoma and primary CNS lymphoma using combined whole-tumor histogram analysis of the normalized cerebral blood volume and the apparent diffusion coefficient. Magn Reson Med Sci 18:53\u201361. https:\/\/doi.org\/10.2463\/mrms.mp.2017-0135","journal-title":"Magn Reson Med Sci"},{"key":"1605_CR45","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.3174\/ajnr.A6211","volume":"40","author":"M Iv","year":"2019","unstructured":"Iv M, Liu X, Lavezo J et al (2019) Perfusion MRI-based fractional tumor burden differentiates between tumor and treatment effect in recurrent glioblastomas and informs clinical decision-making. AJNR Am J Neuroradiol 40:1649\u20131657. https:\/\/doi.org\/10.3174\/ajnr.A6211","journal-title":"AJNR Am J Neuroradiol"},{"key":"1605_CR46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1148\/radiol.2021203071","volume":"299","author":"S Haller","year":"2021","unstructured":"Haller S, Haacke EM, Thurnher MM, Barkhof F (2021) Susceptibility-weighted imaging: technical essentials and clinical neurologic applications. Radiology 299:3\u201326. https:\/\/doi.org\/10.1148\/radiol.2021203071","journal-title":"Radiology"},{"key":"1605_CR47","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.3390\/jcm11237058","volume":"11","author":"A Feindt","year":"2022","unstructured":"Feindt A, Lara-Velazquez M, Alkhasawneh A et al (2022) Post-transplant lymphoproliferative disorder: a rare case of CNS involvement following renal transplant. J Clin Med 11:7058. https:\/\/doi.org\/10.3390\/jcm11237058","journal-title":"J Clin Med"},{"key":"1605_CR48","doi-asserted-by":"publisher","first-page":"426","DOI":"10.3389\/fonc.2019.00426","volume":"9","author":"JD Costabile","year":"2019","unstructured":"Costabile JD, Alaswad E, D\u2019Souza S, Thompson JA, Ormond DR (2019) Current applications of diffusion tensor imaging and tractography in intracranial tumor resection. Front Oncol 9:426. https:\/\/doi.org\/10.3389\/fonc.2019.00426","journal-title":"Front Oncol"},{"key":"1605_CR49","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375\u20132390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"1605_CR50","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/bjh.15263","volume":"182","author":"CB DeStefano","year":"2018","unstructured":"DeStefano CB, Desai SH, Shenoy AG, Catlett JP (2018) Management of post-transplant lymphoproliferative disorders. Br J Haematol 182:330\u2013343. https:\/\/doi.org\/10.1111\/bjh.15263","journal-title":"Br J Haematol"},{"key":"1605_CR51","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","volume":"114","author":"HE Heslop","year":"2009","unstructured":"Heslop HE (2009) How I treat EBV lymphoproliferation. Blood 114:4002\u20134008. https:\/\/doi.org\/10.1182\/blood-2009-07-143545","journal-title":"Blood"},{"key":"1605_CR52","doi-asserted-by":"publisher","first-page":"126","DOI":"10.12659\/AOT.882230","volume":"16","author":"M Izadi","year":"2011","unstructured":"Izadi M, Fazel M, Saadat SH, Taheri S (2011) Radiotherapy is the best treatment method in post transplant lymphoproliferative disorders localizing in brain: a review of the literature. Ann Transplant 16:126\u2013133. https:\/\/doi.org\/10.12659\/AOT.882230","journal-title":"Ann Transplant"}],"container-title":["Insights into Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13244-024-01605-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13244-024-01605-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T05:02:43Z","timestamp":1707886963000},"score":1,"resource":{"primary":{"URL":"https:\/\/insightsimaging.springeropen.com\/articles\/10.1186\/s13244-024-01605-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1186\/s13244-024-01605-y","relation":{},"ISSN":["1869-4101"],"issn-type":[{"value":"1869-4101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"26 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board (IRB) of the First Affiliated Hospital of Guangxi Medical University approved the study (IRB: 2022-E310-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}